STAAR SURGICAL CO - 10-Q Summary (Period Ended June 28, 1996)
Business Context and Reporting Period
This is a quarterly report (Form 10-Q) for STAAR SURGICAL COMPANY for the three and six-month periods ended June 28, 1996. The company manufactures and sells intraocular lenses (IOLs) and related ophthalmic products, with significant international operations, particularly in Europe.
Key Financial Metrics
| Metric | Six Months Ended June 28, 1996 | Six Months Ended June 30, 1995 | |
|---|---|---|---|
| Total Revenues | $19,856,122 | $15,755,340 | |
| Net Income | $3,243,081 | $3,417,505 | |
| Gross Profit Margin | 76.2% | 76.0% | |
| Operating Income | $4,526,441 | $3,192,358 | |
| Cash and Equivalents (End of Period) | $3,872,336 | $3,915,772 | |
| Net Cash from Operating Activities | $2,984,994 | $2,346,618 | |
| Total Debt (Current + Long-term) | $6,284,870 | $5,241,015 | |
| Current Ratio | 2.6:1 | 2.9:1 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 26.0% year-over-year. This was driven by a 64.0% surge in international sales (primarily Europe) due to demand for foldable IOLs and the Glaucoma Wick, and an 11.2% increase in U.S. sales volume.
- Net Income Decline: Despite higher revenues and operating income, net income decreased 5.1% to $3.24 million. This was primarily due to a significant increase in the income tax provision (from 0.7% to 7.4% of revenue) as the company utilized deferred tax assets.
- Expense Management: Marketing and selling expenses decreased as a percentage of revenue (32.2% to 29.9%) due to lower commission rates and efficient international expansion. Research and development expenses increased 29.2% to support new product development.
- Debt and Liquidity: Total debt increased by approximately $1.04 million due to increased borrowings under a refinanced line of credit. Net working capital improved to $16.9 million.
Outlook, Risks, and Management Commentary
- Outlook: Management expects to remain profitable and believes future cash flow needs will be met by operations or additional financing if required.
- Legal Resolution: The company settled all litigation with Alcon during the quarter ended June 28, 1996.
- Risks: International operations expose the company to fluctuating exchange rates, foreign government regulations, and political instability. The company remains involved in litigation to protect its patents and proprietary technology.
- Unusual Items: The income tax provision increased significantly due to the recognition and utilization of net operating loss carryforwards recorded as a deferred tax asset in the prior year.
Investor Verification Checklist
- Verify the sustainability of the 64% international sales growth and exposure to European market dynamics.
- Confirm the impact of the Alcon litigation settlement on future legal expenses and patent protection.
- Monitor the utilization rate of net operating loss carryforwards and its effect on future effective tax rates.
- Review the details of the refinanced line of credit and interest rate implications.
- Assess the return on investment for the increased R&D spending ($1.94M for the six months).